Related Experiment Video
Updated: May 4, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
The expressions of AMACR and iNOS in prostate adenocarcinomas
Tumay Ozgur1, Esin Atik2, Sibel Hakverdi3
1Tumay Ozgur, MD, Assistant Professor, Mustafa Kemal University, School of Medicine, Department of Pathology, Hatay, Turkey.
Background And Objective:
Prostate cancer is the second leading cause of death in men. The localized disease often responds to conventional therapies like androgen ablation via castration and/or administration of chemical inhibitors but advanced disease resistant to any curative therapies is still challenge for investigators. There are increasing efforts to enhance the possibility of finding positive and sensitive immune markers for diagnosing and treating prostate cancer. The aim of this study was to investigate the expression patterns of AMACR and iNOS in prostate adenocarcinomas with different histopathologic grade.
Methodology:
We applied immunohistochemical markers; AMACR and iNOS. Formalin-fixed parafin embedded tissues of 64 prostate needle biopsy specimens diagnosed as prostate adenocarcinoma between 2005-2010 years were included in the study.
Results:
AMACR expression were found in 58 (90.6%) and iNOS expression in 54 (84.4%) of 64 prostate adenocarcinomas. No significant relationship of AMACR and iNOS was obtained (p>0.05). There was no significant correlation of histopathologic grade of the tumors with AMACR and iNOS expression (p>0.05).
Conclusions:
The expression of AMACR and iNOS might be important diagnostic immune markers for prostate adenocarcinomas especially in needle biopsies where the quantity and quality of tissue are limited.
Insights
Alpha-methylacyl-CoA racemase (AMACR) and inducible nitric oxide synthase (iNOS) are highly expressed in prostate adenocarcinomas. These immune markers show potential for diagnosing prostate cancer, especially in limited tissue samples.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Prostate cancer is a leading cause of male mortality.
- Advanced prostate cancer often develops resistance to conventional therapies.
- Identifying sensitive immune markers is crucial for improved diagnosis and treatment.
Purpose of the Study:
- To investigate the expression patterns of AMACR and iNOS in prostate adenocarcinomas.
- To correlate expression levels with histopathologic grade.
Main Methods:
- Immunohistochemical analysis of AMACR and iNOS.
- Study included 64 prostate adenocarcinoma needle biopsy specimens.
Main Results:
- AMACR was expressed in 90.6% and iNOS in 84.4% of cases.
- No significant relationship was found between AMACR and iNOS expression.
- No significant correlation was observed between marker expression and tumor histopathologic grade.
Conclusions:
- AMACR and iNOS expression may serve as valuable diagnostic immune markers for prostate adenocarcinomas.
- These markers are particularly useful in needle biopsies with limited tissue quantity and quality.
More Related Videos
08:40Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
